TY - JOUR
T1 - Serum Contactin-1 in CIDP: A Cross-Sectional Study
AU - Wieske, Luuk
AU - Martín-Aguilar, Lorena
AU - Fehmi, Janev
AU - Lleixà, Cinta
AU - Koel-Simmelink, Marleen J. A.
AU - Chatterjee, Madhurima
AU - van Lierop, Zoë
AU - Killestein, Joep
AU - Verhamme, Camiel
AU - Querol, Luis
AU - Rinaldi, Simon
AU - Teunissen, Charlotte E.
AU - Eftimov, Filip
N1 - Publisher Copyright: Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2021/7/1
Y1 - 2021/7/1
N2 - OBJECTIVE: To investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region. METHODS: Serum contactin-1 levels were measured in 187 patients with CIDP and 222 healthy controls. Paranodal antibodies were investigated in all patients. RESULTS: Serum contactin-1 levels were lower in patients (N = 41) with paranodal antibodies compared with patients (N = 146) without paranodal antibodies (p < 0.01) and showed good discrimination between these groups (area under the curve 0.84; 95% CI: 0.76-0.93). CONCLUSIONS: These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP. CLASSIFICATION OF EVIDENCE: This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%-85%) and a specificity of 97% (95% CI: 83%-100%).
AB - OBJECTIVE: To investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region. METHODS: Serum contactin-1 levels were measured in 187 patients with CIDP and 222 healthy controls. Paranodal antibodies were investigated in all patients. RESULTS: Serum contactin-1 levels were lower in patients (N = 41) with paranodal antibodies compared with patients (N = 146) without paranodal antibodies (p < 0.01) and showed good discrimination between these groups (area under the curve 0.84; 95% CI: 0.76-0.93). CONCLUSIONS: These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP. CLASSIFICATION OF EVIDENCE: This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%-85%) and a specificity of 97% (95% CI: 83%-100%).
UR - http://www.scopus.com/inward/record.url?scp=85111960509&partnerID=8YFLogxK
U2 - https://doi.org/10.1212/NXI.0000000000001040
DO - https://doi.org/10.1212/NXI.0000000000001040
M3 - Article
C2 - 34285092
SN - 2332-7812
VL - 8
JO - Neurology® neuroimmunology & neuroinflammation
JF - Neurology® neuroimmunology & neuroinflammation
IS - 5
ER -